The Utility of Galectin-3 as a Diagnostics and Pharmacotherapy Monitoring Biomarker in Heart Failure (original) (raw)
Evaluation of galectin-3 in patients with heart failure and its relationship with NT-proBNP levels: A case-control study
yonca yılmaz ürün
Journal of surgery and medicine, 2020
View PDFchevron_right
Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience
Grazyna Sygitowicz
Advances in Clinical and Experimental Medicine, 2016
View PDFchevron_right
Galectin-3: a potential biomarker for diagnostics of heart failure
Katarzyna Korzeniowska
2018
View PDFchevron_right
Assessment of galectin-3, cystatin-C and N-terminal B-type natriuretic peptide of serum levels in patients with heart failure
walaa ahmed
Annals of Tropical Medicine and Public Health, 2020
View PDFchevron_right
Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study
karthik sigamani
Cureus
View PDFchevron_right
Galectin-3 in heart failure: high levels are associated with all-cause mortality
Kaspar Broch
International Journal of Cardiology, 2011
View PDFchevron_right
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
Dirk Lok
Annals of Medicine, 2011
View PDFchevron_right
The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study
Johannes Petutschnigg
ESC Heart Failure, 2021
View PDFchevron_right
Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study
Roy Sherwood
International Journal of Cardiology, 2016
View PDFchevron_right
Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study
Patrick Sluss
European Journal of Heart Failure, 2013
View PDFchevron_right
Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure
Alexander Wardeh
Journal of the American Heart Association, 2017
View PDFchevron_right
Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction
Alberto Palazzuoli
Clinica Chimica Acta, 2016
View PDFchevron_right
Utility of plasma galectin-3 in predicting long-term mortality in patients with acute heart failure
dang toan
Biomedical Research and Therapy, 2021
View PDFchevron_right
The GALA study: Relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure
Silvia Sandalinas
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2017
View PDFchevron_right
Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study
Luca Bettari
Circulation: Heart Failure, 2011
View PDFchevron_right
Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure
Umesh Sharma
Journal of The American College of Cardiology, 2006
View PDFchevron_right
GALECTIN-3: A Novel Biomarker for the Prognosis of Heart Failure
Ika Wijaya
Medicine and Pharmacy Reports, 2017
View PDFchevron_right
Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure
Ali Rahimipour
International Cardiovascular Research Journal, 2014
View PDFchevron_right
Prognostic Value of Galectin-3 in Patients with Heart Failure
aleksandar vcev
Disease Markers, 2015
View PDFchevron_right
Galectin-3: A Novel Biomarker of Left Ventricular Remodelling in Chronic Heart Failure
santhi silambanan
Journal of Evidence Based Medicine and Healthcare
View PDFchevron_right
Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure
Caroline Kistorp
BMC Cardiovascular Disorders, 2016
View PDFchevron_right
Galectin-3 as predictor for incident heart failure with preserved ejection fraction in the general population : data from PREVEND
Anneke C Muller Kobold
European Heart Journal, 2012
View PDFchevron_right
Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients
Marco Cardone
Medicine, 2016
View PDFchevron_right
Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure
Pedro Pérez
Frontiers in Cardiovascular Medicine
View PDFchevron_right
Evaluation of Soluble Suppression of Tumorigenicity 2(sST2), N-terminal Pro-brain Natriuretic Peptide (NT-pro BNP) and Galectin‒3 (‒3) in Patients with Heart Failure
Rafid B. Altweel, Rayah Sulaiman Baban
2019
View PDFchevron_right
Galectin-3 in heart failure with preserved ejection fraction
Farzin Fath-Ordoubadi
European Journal of Heart Failure, 2013
View PDFchevron_right
Comparative Study of Circulating Cardiac Biomarker Galectin-3 and Troponin I in Heart Failure Patients
hanan fayed
View PDFchevron_right
The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists
Philippe Rouet
PloS one, 2015
View PDFchevron_right
Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis
Casper Franssen
Journal of the American Heart Association, 2014
View PDFchevron_right
Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure
David Kaye
Scientific Reports
View PDFchevron_right
Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure
Dirk Lok
Clinical Research in Cardiology, 2013
View PDFchevron_right
The Factors Influencing Galectin-3 Levels in Acute Coronary Syndrome with Decreased Left Ventricular Function
Rada Vucic
Acta Facultatis Medicae Naissensis, 2017
View PDFchevron_right